Plain-English translation of NCT07520565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people recover better from acute ischemic stroke when given quickly—within three hours of when the stroke starts. About 1,100 people will participate, with half receiving the new medication and half receiving a placebo (a non-active injection that looks the same). Researchers will measure how well the medication works and whether it is safe.
When a blood clot blocks blood flow to the brain during a stroke, time is critical. This medication is being studied because early treatment might help protect brain cells from further damage and improve how well people recover after a stroke.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive one intravenous injection of either the new medication or a placebo within 3 hours of your stroke. You will be evaluated immediately after the injection, and then have follow-up visits on day 2, day 3, day 10 (or at hospital discharge if earlier), day 30, and day 90. The entire study takes about 3 months, with most visits happening in the hospital or clinic during your recovery.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China